GYRE THERAPEUTICS, INC. Financial Ratios
GYRE / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
9.3%
Profit Margin
8.5%
Net Income / Revenue
Asset Turnover
0.70
Revenue / Total Assets
Equity Multiplier
1.57
Total Assets / Equity
Composite: 9.3% (reported: 9.3%)
Profitability
Liquidity
Current Ratio
5.60
Quick Ratio
5.60
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.70
Inventory Turnover
-
Days Sales Outstanding
97 days
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Earnings Quality
Accrual Ratio
+6.1%
-11.1pp YoY
Earnings include a notable portion of accrual components.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.